Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
The Motley Fool2d
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
“Johnson & Johnson: Buy Rating Reaffirmed Despite Price Target Cut, Growth Prospects Highlighted”
Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Is Johnson & Johnson (JNJ) the Best Diversified Dividend Stock to Buy Now?
We recently compiled a list of the 10 Best Diversified Dividend Stocks To Buy Now. In this article, we are going to take a ...
MassDevice2d
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Hosted on MSN2d
Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat
Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...